Synthetic biology remains nascent, yet full of promise. The idea of using rational engineering approaches to design biology has the potential to solve some of humanity’s biggest challenges, such as securing food supplies or developing new cancer drugs. Despite massive technical progress and increasing global interest in synthetic biology over the last 20 years, this has not yet been translated into significant business growth.

To understand why, and what can be done about it, we hosted a thought-leadership workshop for senior synbio leaders and influencers, to define the obstacles to commercial success and identify the opportunities to resolve these issues by 2023. Participants included end-users, product developers, tools developers and researchers from a range of organisations representing industries from pharmaceuticals to materials.

This report summarises the collective views and captures the key points of those discussions, offering timely and unique insight into how synthetic biology must evolve to be successful, as seen through the eyes of industry leaders.

Download the whitepaper

Richard Hammond
Technology Director and Head of Bioinnovation

As our Head of Bioinnovation, Richard leads our work in biotechnology. Since graduating from University of Cambridge in the mid-nineties, Richard has worked extensively in life sciences and healthcare developing innovative products for both research and clinical applications.